IXHL

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.

Wall Street analysts forecast IXHL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IXHL is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Incannex Healthcare Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

Incannex Healthcare Inc. EPS for the last quarter amounts to -0.02 USD, decreased -93.55 % YoY.

Incannex Healthcare Inc (IXHL) has 12 emplpoyees as of December 17 2025.

Today IXHL has the market capitalization of 143.03M USD.